New Clinical Results Increase Market Potential of Cytotect
• Scientific study: administration of CMV- immunoglobulins reduces risk of tumour diseases following transplants
• Data of more than 40,000 patients analysed
• Transplant doctors discuss practice consequences
DREIEICH, Germany, July 16, 2007--The indication range of Biotest's immunoglobulin, Cytotect®, may be expanded. An article published in the renowned medical magazine "Lancet of Oncology" by Prof. Dr. Gerhard Opelz from the Institute for Immunology at the University of Heidelberg and his colleagues concludes that the administration of Cytotect® significantly reduces the risk of lymphomas following organ transplant surgery. The results are based on the analysis of the data of more than 40,000 patients. The study was acknowledged in a commentary in the same issue of the magazine, which emphasises its significance in scientific terms.
Lymphomas (lymph node cancer) present a formidable complication following transplants, which occurs in 2% to 5% of all patients. The most common cause of these tumors is infection by the Epstein-Barr virus (EBV). Since transplant patients' immune system is inhibited in order to avoid rejection of the transplanted organ, these patients are at particular risk of infection by EBV. Cytotect® is already successfully administered as a prophylaxis against cytomegalovirus infections (CMV) which occur following transplants. Compared to other immunoglobulins, it contains an especially high concentration of antibodies against the Epstein-Barr virus.
On 13 July renown experts in the field of transplantation discussed together with Biotest possible consequences for clinical practice. The participants were in unanimous agreement that the established CMV prophylaxis also has a preventive effect on the formation of EBV-induced lymphomas.
Biotest expects that the new results increase the market potential of Cytotect®.
Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialised in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and serology and microbiology systems which are used, for example, in blood transfusions. Biotest has around 1,200 employees worldwide and its shares are listed in the Frankfurt Stock Exchange's Prime Standard.
Biotest AG, Landsteinerstr. 5
Dr. Marion Wendorff
Tel: +49 (0) 6103 801-520,
Fax: +49 (0) 6103 801-7840
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
Biotest AG Investor Relations Landsteinerstr. 5 63303 Dreieich Phone +49 6103 801-520 Fax 06103 801-7840 e-mail: IR_nachrichten@biotest.de
Posted: July 2007